- 专利标题: NOVEL TARGET FOR ANTI-CANCER EFFECT AND IMMUNITY ENHANCEMENT
-
申请号: EP22785005.4申请日: 2022-04-07
-
公开(公告)号: EP4321174A1公开(公告)日: 2024-02-14
- 发明人: JEON, Bu-Nam , CHA, Mi Young
- 申请人: Genome and Company
- 申请人地址: KR Seongnam-si, Gyeonggi-do 13486 B-8F, 35, Pangyo-ro 255beon-gil, Bundang-gu
- 代理机构: Rückerl, Florian
- 优先权: KR20210046810 20210409
- 国际公布: WO2022216096 20221013
- 主分类号: A61K39/395
- IPC分类号: A61K39/395 ; A61K48/00 ; A61K31/713 ; A61P35/00 ; A61P37/02 ; G01N33/50 ; C07K16/28 ; C07K14/78 ; A61K39/00
摘要:
The present disclosure relates to a pharmaceutical composition for treating or preventing cancer, a pharmaceutical composition for immune-enhancing, a method of screening of anti-cancer agent, and a method of providing information necessary for analysis of cancer prognosis. According to the present disclosure, cancer can be effectively prevented or treated using a CNTN4 inhibitor, and the immunity of subject can be enhanced. In addition, the present disclosure is very useful because it can effectively select new anticancer drug candidates by determining the activity or expression of CNTN4 and can provide information necessary for diagnosing and predicting cancer prognosis.
信息查询